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INTRODUCTION
Mood disorders are highly prevalent in women throughout their lifetime (Pearlstein et al.
1997), being about twice as prevalent in women than men (Alexander et al. 2007; Halbreich
and Kahn 2001; Kessler et al. 1994; Pearlstein et al. 1997). One such mood disorder that affects
females exclusively is premenstrual dysphoric disorder (PMDD). This disorder is characterized
by premenstrual emotional and physical symptoms severe enough to interfere with function
during the last week of the luteal phase of the menstrual cycle, but remit with the onset of
menses. PMDD afflicts 5 – 7% of women in their reproductive years (Pearlstein and Steiner
2008), and although the symptoms of PMDD are of shorter duration than those of other
depressive disorders, the impact of PMDD symptoms on quality of life during the premenstrual
luteal phase is equivalent to that seen with major depressive disorder (MDD), posttraumatic
stress disorder, and panic disorder (Freeman and Sondheimer 2003).
The underlying pathophysiologic mechanisms contributing to PMDD remain elusive. The lack
of a consensus on the biological basis of PMDD and the lack of efficacy of selective serotonin
reuptake inhibitors in up to 40% of PMDD women (Halbreich et al. 2006; Steiner and Soares
2008) speaks to the heterogeneity of PMDD and suggests that there may be clinically distinct
subgroups of PMDD women with differing pathogeneses (Klatzkin et al. 2006a; 2006b).
One such subgroup of PMDD women may be those with a history of MDD. A history of MDD
has been reported in 30–70% of women with PMDD (Cohen et al. 2002; Pearlstein et al.
1990; Yonkers 1997). Not only are PMDD women more likely to have experienced a prior
episode of MDD (Harrison et al. 1989; Pearlstein et al. 1990), but they are also more likely to
develop a future episode of MDD than are non-PMDD women (Hartlage et al. 2001; Roca et
al. 1999). The high comorbidity of PMDD with histories of MDD has fueled debates in the
literature regarding the nosology of the two disorders. For example, it has been suggested that
1) MDD may play a role in the etiology of PMDD (Kendler et al. 1998); 2) PMDD is in fact
a distinct entity when compared to other depressive disorders such as MDD (Endicott et al.
1999); and 3) a history of MDD may have special biological relevance for PMDD
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symptomatology and responses to stress (Klatzkin et al. 2006b). Studies aimed at addressing
the phenotypic similarities and differences seen in women with PMDD relative to women with
histories of MDD may shed light on the extent of overlap in pathogenic pathways and,
consequently, inform treatment for a large proportion of women with PMDD who are otherwise
nonresponsive to current FDA-approved treatments (Halbreich 2008).
Since both PMDD and depressive disorders are associated with increased daily stress (Girdler
et al. 1993; 1998), and are exacerbated by stressful life events (Kendler et al. 2004; Paddison
et al. 1990), a pathogenic role of stress responsive dysregulation has been implicated in both
disorders (Cohen et al. 2002; Endicott 1993; Harrison et al. 1989; Kendler et al. 1998; Pearlstein
et al. 1990; Yonkers 1997). Experimental studies examining stress responses in PMDD women
have been scant, and results mixed. However, when considered together, the majority of
evidence points toward decreased activation of the hypothalamic pituitary adrenal (HPA) and
the sympathetic nervous system (SNS) axes in PMDD women relative to non-PMDD controls.
For example, in both the follicular and luteal phases of the menstrual cycle, PMDD women
show blunted heart rate (HR), blood pressure (BP), and cardiac output reactivity to a variety
of laboratory psychological stressors relative to non-PMDD women (Girdler et al. 1993),
suggesting blunted SNS activation to stressors. Similarly, PMDD women exhibit lower
baseline and stress-induced β-endorphin levels (Chuong et al. 1985; Facchinetti et al. 1994;
Giannini et al. 1990; Straneva et al. 2002), and blunted adrenocorticotropic hormone (ACTH)
and cortisol responses to serotonergic challenges (Bancroft et al. 1991; Su et al. 1997), and
lower cortisol levels during mental stress (Girdler et al., 1998), suggesting blunted HPA-axis
activation.
That PMDD and MDD represent two distinctly different depressive disorders is supported by
evidence suggesting differential dysregulation in the stress axes in women with PMDD versus
women with current or prior depressive disorders. In contrast to the profile seen in PMDD, the
overwhelming evidence in patients with current depression is for a hyperactive HPA-axis
reflected in heightened baseline levels of corticotrophin releasing hormone (CRH), cortisol,
β-endorphin, and ACTH (Carroll et al. 2007; Catalan et al. 1998; Galard et al. 2002; Gold et
al. 1986a; 1986b; 2005; Goodwin et al. 1993; Gotthardt et al. 1995; Heuser et al. 1996; Juruena
et al. 2006; Krittayaphong et al. 1996; Wong et al. 2000; Young et al. 2001; 2000b).
Upregulation of the SNS is also present in patients with current depression, reflected in
increased baseline and stress-induced norepinephrine (NE), SBP, and HR compared to controls
(Carney et al. 1999; 1988; Gold et al. 2005; Hamer et al. 2007; Lake et al. 1982; Lechin et al.
1995; Udupa et al. 2007; Veith et al. 1994; Volkers et al. 2003; Wong et al. 2000). With regard
to SNS and HPA-axis functioning in euthymic individuals with a history of MDD, most studies,
though not all (Ahrens et al. 2008), report hyperactivity of both stress axes (Broadley et al.
2005; Davydov et al. 2007; Kathol 1985; Young et al. 2000a), indicating persistent
dysregulation beyond the remission of the depressive disorder.
Another clinically significant aspect of both PMDD and MDD that may have relevance for the
nosology of these mood disorders are the physical, or somatic symptoms that are common to
both. Somatic symptoms such as breast tenderness, bloating, and joint or muscle pain are
important features of PMDD and MDD and contribute to overall dysfunction (Steiner et al.
2001). Although laboratory-based methods of assessing pain sensitivity are positively related
to clinical pain (Edwards and Fillingim 1999; Fillingim et al. 1999), there are few studies
assessing pain sensitivity in PMDD (Fillingim et al. 1995; Kuczmierczyk and Adams 1986;
Kuczmierczyk et al. 1986; Straneva et al. 2002) and MDD patients (Klauenberg et al. 2008;
Bar et al. 2005; 2006; Dickens et al. 2003; Lautenbacher et al. 1994; 1999; Schwier et al.
2009; Terhaar et al. 2009).
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Prior studies from our laboratory have shown that women with PMDD exhibit lower ischemic
pain threshold and tolerance compared with controls in both the follicular and luteal phases of
the menstrual cycle (Fillingim et al. 1995; Straneva et al. 2002), and others have shown that
PMDD women endorse higher pain intensity ratings in response to pressure pain irrespective
of menstrual cycle phase (Kuczmierczyk and Adams 1986; Kuczmierczyk et al. 1986). These
results, taken together, suggest that PMDD is associated with enhanced pain sensitivity. In
contrast, a systematic review and meta-analysis of the literature in MDD concluded that pain
threshold was higher in individuals with current MDD compared to healthy controls (Dickens
et al. 2003). More recent studies have assessed both threshold and tolerance to multiple
experimental pain stimuli in depressed patients, and although findings have been mixed, taken
together they indicate reduced sensitivity to experimental pain in MDD (Bar et al. 2005;
2006; Klauenberg et al. 2008; Lautenbacher et al. 1994; 1999; Schwier et al. 2009; Sindrup
and Jensen 1999; Terhaar et al. 2009;). To the extent that pain sensitivity is modulated by stress
responsive systems (e.g. stress-induced analgesia) (al’Absi et al. 2002; Girdler et al. 2005;
Maixner 1991; Mechlin et al. 2005), diagnosis-related differences in stress responses may play
a role in the experience of pain in both PMDD and MDD patients.
Consequently, the primary purpose of the current study was to examine evidence for common
versus different phenotypic profiles related to SNS, HPA and pain measures in women with
PMDD and women with histories of MDD, and whether a history of MDD holds special
relevance for PMDD women with respect to stress and pain profiles. Although a diagnosis of
current MDD may be superimposed on the diagnosis of PMDD (American Psychiatric
Association [DSM-IV], 1994), this comorbidity is less common than is a history of MDD in
PMDD samples. Hence, our focus was on histories of MDD, and not current MDD in women
with PMDD. While the present investigation is exploratory in nature, it is the first, to our
knowledge, to approach this issue experimentally with the inclusion of four groups of women:
1) PMDD women with histories of MDD; 2) PMDD women with no history of MDD; 3) non-
PMDD women with histories of MDD; and 4) non-PMDD women with no history of MDD.
Diagnosis-related differences in phenotypes would be supported by statistical main effects of
prior MDD or PMDD in the absence of PMDD × Prior MDD interactions. On the other hand,
if histories of MDD hold special relevance for the SNS, HPA-axis, and/or pain sensitivity
measures in PMDD women (or if the effects of PMDD and prior MDD were additive), then
we would anticipate PMDD × Prior MDD interactions in these measures.
METHODS
Participants
The sample of 54 women (19–51 years of age) who comprise this report represent a sub-sample
of participants recruited for a larger, ongoing investigation. The participants in this substudy
were specifically recruited via newspaper, radio, or posted advertisements to examine the
influence of histories of MDD and PMDD diagnosis on pain sensitivity and stress responses.
While it was not necessary to engage in selective recruitment efforts targeting PMDD women
with histories of MDD, in order to recruit non-PMDD controls with prior MDD, a proportion
of our advertisements targeted women with a prior MD episode. Since the ongoing parent
project is not focused on histories of MDD, the participants comprising this report represent
the final sample of participants for the substudy related to PMDD and histories of MDD and
are composed of four groups: 1) Non- PMDD women with no prior MDD (N = 18); 2) non-
PMDD women with prior MDD (N = 9); 3) PMDD women with no prior MDD (N = 17); 4)
PMDD women with prior MDD (N = 10).
Participants with a current Axis I psychiatric disorder were excluded (based on interview, see
below) but referred for treatment. Also excluded was any woman who was pregnant or
breastfeeding, had irregular menstrual cycles, was taking prescription medication (including
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oral contraceptives and psychotropics), had a cardiovascular disorder, a history of or a current
chronic or acute pain condition, an endocrine disorder including diabetes or thyroid disorder,
or other chronic medical illness. A diagnosis of MDD was based on a structured clinical
interview (see below) with the requirement of one year in full remission. Participants in the
prior MDD group were required to have had at least one prior episode of MDD, though they
may also have had histories of minor depression, dysthymia, or adjustment disorder with
depressed mood. The never depressed groups were free of any lifetime depressive illness,
including minor depression and adjustment disorder. The protocol was approved by the
institution’s Institutional Review Board, and all participants provided informed, written
consent before participating. Participants received $100 compensation.
Procedures
Screening and Enrollment—After an initial phone-screening interview, each participant
was scheduled for an enrollment session. During this session, informed consent was obtained,
a series of stethoscopic blood pressures was taken, and participants underwent a diagnostic
interview using the MINI International Neuropsychiatric Interview for Axis I disorders
(Sheehan et al. 1998). Also, because one goal of the ongoing parent project is to examine the
influence of abuse histories on pain sensitivity and stress responses, a validated structured
interview to assess previous abuse experiences (Leserman et al. 1997) was also administered.
Once determined to be eligible, participants were instructed on the Daily Record of Severity
of Problems (DRSP) form (Endicott et al. 2006), which they were asked to fill out daily for 2–
3 consecutive menstrual cycles in order to confirm the diagnosis of PMDD. Upon completion
of the DRSP ratings, participants underwent a second screening visit where they were instructed
on the use of home ovulation testing kits that were used to target the testing session during the
late luteal (symptomatic) phase.
Confirming PMDD Diagnosis—The DRSP (Endicott et al. 2006) was used to confirm
PMDD and non-PMDD status for all participants. The DRSP consists of 24 symptoms
(depressed, hopeless, worthless or guilty, anxious, mood swings, more sensitive, angry or
irritable, conflict, less interest, difficulty concentrating, fatigue, increased appetite or overate,
food cravings, slept more, trouble sleeping, overwhelmed, out of control, breast tenderness,
breast swelling or bloating, headache, joint or muscle pain, less productivity or efficiency due
to above problems, interference with hobbies or social activities due to above problems, and
interference with relationships due to the above problems), rated on a severity scale from 1
(not present) to 6 (extreme). In order to discourage retrospective reporting, completed forms
were mailed back weekly. To classify participants with PMDD, each met the following criteria
(Endicott et al. 2006): 1) During the seven day window prior to menses, a score of 4 (moderate
severity) or greater was required on at least two days on at least five of the items assessing
mood state listed above; 2) During the seven day window prior to menses, a score of at least
4 (moderate) or greater was required on at least two days for at least one of the items assessing
functional impairment listed above; 3) At least a 30% increase in total symptom severity score
was required (see Data Analysis) during the seven days preceding menses compared with
follicular phase days 4–10; 4) criteria 1–4 were met on two menstrual cycles.
Non-PMDD women met the following criteria: 1) no more than mild emotional symptoms
occurring during the premenstrual days; 2) no evidence for functional impairment associated
with emotional symptoms; 3) these criteria were met on two menstrual cycles.
Test Session—Each of the participants were tested once during the luteal phase of the
menstrual cycle, 5–12 days after home urine testing revealed the luteinizing hormone surge
that preceded ovulation (corresponding to days 18–25 of an idealized 28 day cycle). Cycle
phase was subsequently confirmed to be ovulatory based upon serum progesterone. We tested
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in the luteal (symptomatic) phase only, since there is little consistent evidence that menstrual
cycle phase influences blood pressure (BP) or heart rate (HR) in healthy controls (Stoney et
al. 1990; Weidner and Helmig 1990) or BP, HR, and neuroendocrine differences between
PMDD and non-PMDD groups at rest or during stress (Girdler et al. 1993; 1998; Straneva et
al. 2002; Su et al. 1997).
All laboratory testing began between the hours of 7:00am and 9:30am. The laboratory visit
lasted approximately three hours and thirty minutes and followed a fixed sequence. The order
of testing was as follows: 1) Instrumentation for BP monitoring (Suntech 4240 Exercise BP
monitor) and stethoscopic BP assessments to ensure reliable cuff placement and microphone
position; 2) I.V. setup and recovery; 3) Baseline 1 Rest; 4) Beck Depression Inventory and
Spielberger State Anxiety Inventory; 5) Pain Testing; 6) Recovery; 7) Baseline 2 Rest; 8) Trier
Social Stress Test. These events are described more fully below.
I.V. Setup—A research nurse inserted a butterfly needle into a forearm vein. A non-
heparinized, multi-stop-cock system was employed, which allowed the nurse to draw blood
samples without the added stress involved in multiple venipunctures. Participants recovered
for 15 minutes following IV placement.
Baseline 1 Rest—Quiet rest ensued for a subsequent 10 minutes. BP and HR measures were
taken at minutes 1, 3, 6, and 9, and averaged. Blood was sampled at min 10 for norepinephrine
(NE), β-endorphin, cortisol, and for progesterone.
Pain Testing Procedures—Participants were exposed to two pain tests. One of two task
orders was used, counterbalancing order across PMDD and prior MDD groups.
The Submaximal Effort Tourniquet Procedure
In this procedure, as described previously (Maixner et al. 1990), a tourniquet cuff was
positioned on the participant’s arm and the arm placed to the side. Before inflating the
tourniquet cuff to 200 mm Hg (Hokanson E20 Rapid Cuff Inflator), the participant’s arm was
raised for 30 seconds to promote venous drainage, and then the cuff was inflated, the
experimenter’s stopwatch started, and the arm returned to the side. To promote forearm
ischemia, participants engaged in 20 handgrip exercises at 30% of their maximum force with
an intersqueeze interval of 2 seconds. Participants were instructed to indicate when the
sensations in their arm first became painful (pain threshold) and when they were no longer
willing or able to tolerate the pain (pain tolerance). A maximum time limit of 20 minutes was
enforced, though participants were not informed of this limit.
Hand Cold Pressor
The apparatus for the cold pressor consisted of a container filled with ice and water that was
maintained at 4°C as recorded immediately before initiating the test. The use of a water
circulator prevented the water from warming near the participant’s hand. At the onset of the
test, participants were instructed to submerge their hand to the marked line on their wrist and
to remain still. Participants were instructed to indicate to the experimenter when the sensations
in their hand first became painful (pain threshold) and to also indicate when they were no longer
willing or able to tolerate the pain by saying “stop” (pain tolerance). A maximum time limit
of 5 minutes was imposed, though participants were not informed of this limit.
Pain intensity and unpleasantness ratings were obtained for both the cold pressor and tourniquet
ischemic pain tasks. Participants were instructed that at the point of tolerance for each pain
task, they would be asked to rate the intensity and unpleasantness of their pain using separate
visual analog scales (0 to 100). Thus, immediately before deflating the tourniquet cuff and
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immediately before removal of the hand from the ice bath, the experimenter held up one visual
analog scale for intensity rating, with the 100-cm line anchored by the words “not at all intense”
and “the most intense pain imaginable.” Next, the experimenter held up the scale for
unpleasantness, with the 100-cm line anchored by the words “not at all unpleasant” and “the
most unpleasant pain imaginable.”
Recovery—A five minute recovery followed each pain task.
Baseline 2 Rest—Following the recovery period, quiet rest ensued for an additional 10
minutes, serving as a baseline from which to calculate cardiovascular reactivity. BP and HR
measures were taken at minutes 1, 3, 6, and 9 and averaged. Blood was sampled at min 10 for
baseline levels of NE, β-endorphin, and cortisol.
The Trier Social Stress Test (TSST)—A modified version of the TSST (Kirschbaum et
al. 1993) was employed (modified to include serial addition as opposed to serial subtraction).
The TSST is a stress test which reliably induces large and consistent HPA-axis and
cardiovascular responses (Kirschbaum et al. 1993; 1995a; 1995b). The TSST involves four
components: 1) Pre-Task Instructions (5 min) during which time participants are introduced
to the ‘selection committee’ who will later listen to their job talk. Participants are also given
the instructions for the mental arithmetic task. The duration of the instruction period averaged
5 minutes; 2) Speech Preparation Period (5 min): Participants were told that they should
imagine that they are applying for their ideal job and were then left alone for 5 minutes to
prepare their talk describing why they would be the ideal candidate for the position; 3) Job
Speech (5 min): immediately following the preparation period, the selection committee
returned to the testing room and asked the participant to deliver her talk describing to the
committee why she would be the perfect applicant for the position. If the participant finished
before 5 minutes, the committee responded in a standardized way, with prepared questions to
ensure that the participant spoke for the entire period; and 4) Paced Auditory Serial Addition
Test (PASAT; (Gronwall 1977)) (8.5 min) involves the tape recorded presentation of numbers
from 1 – 9. Participants are to add each number presented on the tape to the immediately
preceding number and to state the answer aloud. There are four series of numbers, with
progressively shorter inter-digit intervals (2.4, 2.0, 1.6, and 1.2 seconds). The experimenter
remained in the room to monitor performance.
Task Assessments—Task assessment questionnaires were administered after the cessation
of each pain task, as well as at the end of the TSST. Using a visual analog scale, the participants
rated: 1) how difficult they found the task; 2) how tense they were during the task; 3) how well
they were able to concentrate during the task; and 4) how much effort they put into the task.
Cardiovascular and Neuroendocrine Sampling During TSST—All measurements
took place while participants were in a comfortable seated position. BP and HR measures were
taken at minutes 1, 3, and 5 of the Speech Preparation Period, minutes 1, 3, and 5 of the Job
Speech, and minutes 2, 4, 6, and 8 of Serial Addition and averaged to constitute task levels.
NE was sampled at the end of minute 2 of Speech and minute 2 of Serial Addition since
catecholamines peak within the first minutes of stress and have a short half-life (3 min)
(Dimsdale and Ziegler 1991).
Our markers for assessing the HPA-axis were cortisol and β-endorphin, and these levels were
assessed at minute 10 of Baseline 2 Rest. We were unable to assess these factors in response
to stress since, due to logistical reasons, our laboratory study protocol was restricted to early
morning hours when the diurnal effects on the HPA-axis are significant and prevent valid
assessment of cortisol and β-endorphin stress reactivity (Clow et al. 2004; Cohen et al. 2006;
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Restituto et al. 2008). Thus, we restricted our analyses involving HPA-axis measures to
Baseline rest concentrations only.
Rationale and Selection of Biomarkers
The cardiovascular biomarkers chosen in the present study to reflect the SNS axis were SBP,
DBP, and HR (though HR is also determined by parasympathetic cardiac drive), since previous
research has shown them to be sensitive to diagnosis related differences involving both PMDD
and MDD (Carney et al. 1999; 1988; Hamer et al. 2007; Lechin et al. 1995; Girdler et al.
1993; 2007; Udupa et al. 2007; Volkers et al. 2003). Plasma NE was selected as the
neuroendocrine biomarker of SNS activity since it is reflective of sympathetic nerve activity
(Goldstein et al., 1983) and has consistently differentiated PMDD and MDD patients from
controls (Girdler et al., 1998; Gold et al. 2005; Lake et al. 1982; Veith et al. 1994; Wong et al.
2000). Cortisol was selected as the biomarker of basal HPA-axis activity since it has been
shown to differentiate PMDD and MDD patients from controls (Bancroft et al. 1991; Carroll
et al. 2007; Catalan et al. 1998; Galard et al. 2002; Girdler at al., 1998; Gold et al. 1986a;
1986b; 2005; Goodwin et al. 1993; Gotthardt et al. 1995; Heuser et al. 1996; Juruena et al.
2006; Su et al. 1997; Wong et al. 2000; Young et al. 2001; 2000b), while β-endorphin was
selected as an additional HPA-axis biomarker since it is released from both the hypothalamus
and the pituitary gland and plays a key role in the suppression of pain sensations (Berne and
Levy, 1998), it has been shown to be correlated with sensitivity to experimental pain (al’Absi
et al.,2002; Girdler et al., 2005; Mechlin et al., 2005; Straneva et al., 2002), and it differs as a
function of both PMDD and MDD diagnoses (Chuong et al. 1985; Facchinetti et al. 1994;
Giannini et al. 1990; Goodwin et al., 1993; Krittayaphong et al., 1996; Straneva et al. 2002;
Young et al., 2000b),
Measurements
Blood Pressure and Heart Rate—The Suntech Exercise BP monitor, Model 4240
(SunTech Medical Instruments, Inc., Raleigh, NC) provided automated measurement of BP
and HR during the sessions. The Suntech Exercise BP monitor uses the auscultatory technique,
with R-wave Gating. This BP monitor is accurate within +/− 2 mmHg between 0 mmHg and
300 mmHg. Prior to initiating the baseline rest period, five standard stethoscopic blood
pressures were taken simultaneously with the automated pressures in order to ensure correct
microphone placement and cuff positioning.
Plasma Norepinephrine—Norepinephrine concentrations were determined using the
ELISA (Enzyme-Linked ImmunoSorbent Assay) method, and employing a kit from ALPC
Diagnostics. The sensitivity of the assay is 0.9 pg/mL, and the intra- and inter-assay coefficients
were 5% and 6.1% respectively.
Plasma cortisol and serum progesterone—Plasma cortisol and serum progesterone
were determined using radioimmunoassay techniques commercially available from ICN
Pharmaceuticals, INC. The specificity of the antiserum for progesterone is very high, showing
only 0.05–2.5% cross-reactivity with other steroid compounds, and the sensitivity of the assay
is 0.01 ng/mL. The intra- and inter-assay coefficients of variation from the progesterone assay
were approximately 5.2% and 10.9%, respectively. Luteal phase progesterone levels <3 mg/
ml were considered reflective of an anovulatory cycle. For cortisol, the sensitivity of the assay
is 0.07 μg/dL and the specificity is high, showing 0.05–2.2% cross-reactivity with similar
compounds, except prednisolone, where 94% cross-reactivity is obtained. The intra- and inter-
assay coefficients of variation from the cortisol assay were approximately 3% and 9.8%,
respectively.
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Plasma β-endorphin—Plasma β-endorphin levels in EDTA plasma were determined using
the ELISA method, and employing a kit from MD Biosciences. The intra- and inter-assay
coefficients of variation from the assay were approximately 6% and 12%, respectively, and
the assay sensitivity was 0.18 μg/ml.
DATA ANALYSIS
Demographics
Group differences in demographic factors, state anxiety and depression scores assessed during
the laboratory protocol, and baseline SNS and HPA-axis factors were examined using a 2
(PMDD: yes vs. no) × 2 (Prior MDD: yes vs. no) ANOVA or chi square analyses. In order to
assess whether the proportion of PMDD women as well as the proportion of women with a
history of MDD differed by minority race, a 2 (PMDD) × 2 (Prior MDD) × 2 (Race: Non-
Hispanic Whites vs. Minorities: African American, Hispanic, Asian, or Multi-racial) chi square
analysis was utilized. Similarly, a 2 (PMDD) × 2 (Prior MDD) × 2 (Abuse: yes vs. no) chi
square analysis was performed to determine whether the proportion of women with an abuse
history differed by PMDD or Prior MDD status. Because we detected marginally greater abuse
rates in non-PMDD women with prior MDD relative to non-PMDD women with no prior MDD
(see Table 1), all analyses employed abuse histories (Yes = 1, No = 0) as a covariate. Although
the covariate of abuse history was non-significant for all analyses (all ps > .05), it was retained
nonetheless as a more conservative analytic approach. Finally, for women with prior MDD,
PMDD and non-PMDD groups were compared on months since last major depressive episode
and number of prior MDD episodes with a one way ANOVA. Where significant interactions
emerged, simple effects analyses conducted separately in MDD or PMDD groups were
conducted to explore the source of the interaction.
Daily Symptom Ratings
For each of the 24 DRSP symptoms, a follicular (days 4 through 10) and luteal (days -7 through
-1 before menses) phase average was calculated for cycle one and cycle two, and cycle one
and cycle two were averaged to create an overall follicular and an overall luteal phase average.
Next, each symptom was placed into one of five core symptom categories (Endicott et al.
2006): 1. Somatic (fatigue, breast tenderness, breast swelling or bloating, headache, joint or
muscle pain); 2. Depression: (depressed, hopeless, worthless or guilty, slept more, trouble
sleeping, overwhelmed); 3. Anger/Irritability: (anger or irritability, conflict); 4. Anxiety:
(anxiety); and 5. Impairment: (less productivity or efficiency, interference with hobbies or
social activities, interference with relationships), and averaged to yield one total follicular and
luteal score for each of the five core categories.
Women were assessed for differences in the five core symptom categories using a 2 (PMDD)
× 2 (Prior MDD) × 2 (Menstrual Cycle Phase) repeated measures ANOVA with Menstrual
Cycle Phase as the repeated factor. Where significant interactions emerged, simple effects
analyses conducted separately in MDD or PMDD groups were conducted to explore the source
of the interaction.
Hypothalamic Pituitary Adrenal (HPA)-Axis and Sympathetic Nervous System (SNS)
Group differences in baseline cortisol and β-endorphin were analyzed using a 2 (PMDD) × 2
(Prior MDD) ANOVA. Next, cardiovascular and NE stress responsivity based on PMDD and
Prior MDD status were examined by calculating delta scores (Stress task – Baseline) and
performing a 2 (PMDD) × 2 (Prior MDD) × 2 (Stress Task: Speech vs. Math) repeated measures
ANOVA with stress task as the repeated factor.
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Pain Sensitivity for Cold Pressor and Tourniquet Ischemic Tasks
To determine diagnosis-related differences in pain sensitivity, a 2 (PMDD) × 2 (Prior MDD)
× 2 (Period: Threshold vs. Tolerance) repeated measures ANOVA with Period as the repeated
factor was performed separately for the ischemic and cold pressor pain task since these pain
tasks differ in their endogenous pain regulatory mechanisms (e.g. opioid versus non-opioid,
respectively) (Frid et al., 1979; Girdler et al., 2005; Schull et al., 1981). Pain intensity and
unpleasantness ratings from 0–100 given immediately following voluntary tolerance for each
pain task were analyzed using a 2 (PMDD) × 2 (Prior MDD) ANOVA. Where significant
interactions emerged, simple effects analyses were conducted separately in MDD or PMDD
groups to examine the source of the interaction.
Task Assessments
The participants’ experiences of each pain and stress task (difficulty, tension, inability to
concentrate, effort) as measured by the task assessment questionnaire was analyzed by PMDD
and Prior MDD status using a 2 (PMDD) × 2 (Prior MDD) ANOVA. The analyses were
performed separately for each pain and stress task and for each of the 4 items on the task




As seen in Table 1 there were no group differences in age, BMI, state anxiety, or minority race
(ps > .05). PMDD women had higher BDI scores than non-PMDD women (F(4, 53) = 11.5, p
< .01), results that would be expected during the symptomatic luteal phase of the menstrual
cycle when the inventory was administered. In addition, a marginally greater proportion of
non-PMDD women with prior MDD had an abuse history relative to non-PMDD women with
no prior MDD (χ2 = 3.8, p = .05). Lastly, in analyses performed in women with prior MDD
only, PMDD and non-PMDD women did not differ in number of prior episodes of MDD or
months in remission from MDD (all ps >.05).
Daily Symptom Ratings
As expected, for non-PMDD women, no menstrual cycle-related differences in any core
symptom category were present (all ps > .05), while for PMDD women, symptom severity was
significantly greater in the luteal phase than the follicular phase for each core symptom category
(all ps < .0001) (Figure 1). While in general, women with PMDD reported greater severity of
somatic symptoms (F(1, 49) = 100.3, p < .0001), depression (F(1, 49) = 82.3, p < .0001), anger/
irritability (F(1, 49) = 76.8, p < .0001), anxiety (F(1, 49) = 56.9, p < .0001), and impairment
(F(1, 49) = 68.0, p < .0001) than non-PMDD women, PMDD × Menstrual Cycle Phase
interactions were present for all symptom categories [somatic (F(1, 49) = 66.4, p < .0001),
depression (F(1, 49) = 57.4, p < .0001), anger/irritability (F(1, 49) = 94.1, p < .0001), anxiety
(F(1, 49) = 111.7 p < .0001), and impairment (F(1, 49) = 49.5, p < .0001)], reflecting the
significantly greater PMDD-related differences for somatic symptoms, depression, and
impairment in the luteal phase than in the follicular phase. For the symptoms of anger/
irritability (F(4, 53) = 117.5, p < .0001) and anxiety (F(4, 53) = 125.7, p < .0001), however,
the PMDD-related differences were isolated to the luteal phase only.
Hypothalamic Pituitary Adrenal Axis Biomarkers
As seen in Table 2 and Figure 2, the omnibus ANOVA revealed a PMDD × Prior MDD
interaction for cortisol (F(4, 50) = 5.8, p < .05). The source of this interaction was assessed
with a simple effects analysis conducted separately in each MDD group, indicating that PMDD
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women had lower baseline cortisol concentrations than non-PMDD women, but only if a
history of MDD was present (F(2, 16) = 4.5, p = .05). In contrast, there were no diagnosis-
related differences in baseline β-endorphin (all ps > .05) (Table 2).
Sympathetic Nervous System Biomarkers
Despite no diagnosis-related differences for HR, SBP, DBP, or NE at baseline rest (Table 2),
the omnibus ANOVA indicated a main effect of PMDD diagnosis for DBP (F(1, 47) = 8.1, p
< .01) and NE (F(1, 38) = 6.0, p < .05) reactivity to stress since PMDD women had blunted
reactivity relative to non-PMDD women, regardless of MDD histories (Figures 3 and 4). The
omnibus test also revealed a PMDD × Stress Task interaction for HR (F(1, 48) = 10.8, p < .
01). Subsequent simple effects analyses conducted separately by task revealed that regardless
of MDD histories, PMDD women had blunted HR responses to the speech task relative to non-
PMDD women (F(4, 52) = 7.0, p < .05). Furthermore, the omnibus ANOVA also indicated
that women with a history of MDD, regardless of PMDD status, displayed greater DBP stress
reactivity than women with no history of MDD during both stressors (F(1, 47) = 4.7, p < .05).
No diagnosis-related differences in the SBP response to stress were present (all ps > .05).
Speech and Math Task Assessments
A seen in Table 3, the omnibus tests revealed that PMDD women, regardless of MDD history,
reported more difficulty (F(3, 52) = 6.3, p < .05), more tension (F(4, 52) = 9.5, p < .01), and a
greater inability to concentrate (F(4, 52) = 15.5, p < .001) during speech stress than non-PMDD
women. No diagnosis-related differences for self-reported effort were present for the speech
stressor (all ps > .05).
For math stress, the omnibus ANOVA revealed that PMDD women, regardless of MDD
history, reported greater inability to concentrate than non-PMDD women (F(4, 52) = 7.9, p < .
01), while women with prior MDD, regardless of PMDD, reported greater difficulty than
women with no prior MDD (F(4, 52) = 4.5, p < .05) (Table 3). No diagnosis-related differences
for self-reported tension or effort were present for the math stressor (all ps > .05).
Pain Sensitivity to Cold Pressor and Tourniquet ischemic Tasks
Cold Pressor Task—For the cold pressor task, the omnibus ANOVA revealed a PMDD ×
Prior MDD interaction (F(1, 48) = 4.0, p = .05). Subsequent simple effects analyses conducted
separately in PMDD and non-PMDD women revealed that only in non-PMDD women were
women with prior MDD less sensitive to cold pressor pain than women with no prior MDD (F
(1, 23) = 4.6, p < .05; see Figure 5).
Tourniquet Ischemic Task—Although the same pattern of effects was present for
tourniquet ischemic pain sensitivity (i.e., less sensitivity in non-PMDD women with prior
MDD), the PMDD × Prior MDD interaction failed to reach conventional levels of statistical
significance.
Pain Intensity and Unpleasantness Ratings and Task Assessments
As summarized in Table 4, the omnibus ANOVA revealed a PMDD × Prior MDD interaction
for cold pressor unpleasantness (F(4, 53) = 4.1, p < .05). Subsequent simple effects analyses
conducted separately in those with versus without a history of MDD indicated that only in
women with a history of MDD did PMDD women report greater cold pressor pain
unpleasantness than non-PMDD women (F(2, 18) = 11.1, p < .01). No significant differences
in the task assessments (difficulty, tension, inability to concentrate, and effort) were found for
the cold pressor task (ps > .05).
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For the tourniquet ischemic task, the omnibus ANOVA revealed that women with a history of
MDD reported less pain intensity than did women with no history of MDD, regardless of
PMDD status (F(4, 53) = 4.1, p< .05), although no group differences were found for tourniquet
ischemic unpleasantness (ps > .05). The omnibus test also revealed a PMDD × Prior MDD
interaction for reported effort during the tourniquet ischemic task emerged (F(4, 53) = 5.4, p
< .05). Subsequent simple effects analyses conducted separately as a function of MDD
diagnosis indicated that only in women with prior MDD did PMDD women report putting forth
more effort than non-PMDD women (F(2, 18) = 5.7, p < .05). No group differences were present
for difficulty, tension, and inability to concentrate (all ps > .05).
DISCUSSION
The results of the present investigation suggest unique phenotypic differences associated with
PMDD and a history of MDD with respect to cardiovascular and neuroendocrine stress-
responsive factors. At the same time, however, our results also indicate that histories of MDD
may hold special relevance for PMDD women, at least with respect to the HPA-axis and pain
sensitivity.
The chief finding of our study that supports a consistent phenotypic difference between PMDD
and MDD diagnoses was the observation that PMDD women, regardless of whether they have
a history of MDD, show blunted stress reactivity in biomarkers reflecting sympathetic nervous
system (SNS) activation relative to non-PMDD women. This was true for BP, HR and plasma
NE and is consistent with other prior reports in PMDD samples (Girdler et al. 1993; 1998), but
adds to that prior literature by controlling for histories of MDD.
In contrast, after controlling for histories of MDD, we did not find evidence for heightened
sensitivity to experimental pain as reflected in pain threshold or tolerance levels that has
previously been reported in PMDD cohorts (Fillingim et al. 1995; Kuczmierczyk and Adams
1986; Kuczmierczyk et al. 1986; Straneva et al. 2002), though we did find that in women with
no prior MDD history, PMDD women reported greater pain unpleasantness than non-PMDD
women. On the other hand, the most robust evidence for diagnosis related differences in pain
sensitivity was seen in non-PMDD women with histories of MDD who differed from all other
women in their greater cold pressor threshold and tolerance levels. Moreover, all women with
prior MDD, regardless of the PMDD diagnosis, exhibited lower pain intensity ratings to the
cold pressor test as well. Given that up to 37% of non-PMDD women would be expected to
have a history of MDD (Weiss et al. 1999), the absence of controlling for histories of MDD in
all prior studies of PMDD may have contributed to the findings for decreased experimental
pain sensitivity in non-PMDD women relative to PMDD women (Fillingim et al. 1995;
Kuczmierczyk and Adams 1986; Kuczmierczyk et al. 1986; Straneva et al. 2002).
It is worth underscoring that one remarkable feature of our findings is that, on average, the
non-PMDD women with prior MDD, who showed the markedly elevated cold pressor pain
threshold and tolerance levels, had been in full remission from their last MDD episode for
nearly five years. While other studies, including a recent meta-analysis, have reported
decreased pain sensitivity in patients with current MDD (Bar et al. 2005; 2006; Lautenbacher
et al. 1994; 1999; Sindrup and Jensen 1999), our results add to two other reports in the literature
documenting the persistence of this hypoalgesia in patients in remission from their MDD.
Specifically, Bar and colleagues (2003) reported increased thermal pain threshold and tolerance
in euthymic women with a history MDD compared to controls, and a recent study from our
laboratory showed that women with a history of mood disorders were less sensitive to
tourniquet ischemic pain than women with no history of a mood disorder (Klatzkin et al.
2007). Thus, the results of the current investigation add to the evidence that histories of MDD
are associated with persistent alterations in pain sensitivity in women, particularly women
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without comorbid PMDD. Taken together, our preliminary findings suggest that altered
sensitivity to experimental pain is more likely a phenotypic feature of histories of MDD than
it is of PMDD.
Given the well documented evidence that, relative to men, women have increased clinical pain
(Unruh 1996) and also show decreased experimental pain tolerance (Riley et al. 1998; Sheffield
et al. 2000), it may seem paradoxical that women with a history of MDD, who also have
increased clinical pain (Bromberger et al. 2005), show decreases sensitivity to experimental
pain stimuli. Lautenbacher and Krieg (1994) have addressed this paradox by hypothesizing
that diminished processing of painful stimuli could be responsible for both phenomena. The
authors argue that reduced processing of nociceptive stimuli at both spinal and subcortical
stages may cause hypoalgesia to phasic experimental pain, and at the same time cause
hyperalgesia to endogenous clinical pain due to deficient activation of inhibitory systems. This
theory is supported by Bar et al. (2005) who found increased pain sensitivity to ischemic pain
(deep somatic pain), but decreased pain sensitivity to heat and electric pain (phasic surface
pain) in patients with current MDD compared to controls. Although Lautenbacher et al.
(1999) failed to find a significant correlation between clinical pain complaints and pain
threshold in depressed patients, this does not rule out the possibility that alterations in central
and peripheral pain processing contribute to both phenomena (i.e. increased clinical pain but
decreased sensitivity to acute experimental pain). Thus, our results indicating that women with
a history of MDD continue to display dysfunctions in pain regulation are consistent with the
vast majority of the literature on experimental pain sensitivity in MDD and may well relate to
the increased clinical pain reported in the disorder.
In addition to evidence for persistent disturbance in pain sensitivity associated with histories
of MDD, and consistent with the literature in patients with current MDD who show heightened
sympathetic reactivity to stress (Carney et al. 1999; Hamer et al. 2007; Lechin et al. 1995), our
study found that women with histories of MDD, regardless of PMDD status, showed
heightened DBP reactivity to mental stressors relative to never depressed women. While others
have shown increased activation of the HPA-axis in euthymic individuals with histories of
depression (Kathol 1985; Pintor et al. 2007; Trestman et al. 1991; Young et al. 2000a), findings
that are consistent with our observation for elevated basal cortisol levels in non-PMDD women
with prior MDD, this is the first study to our knowledge to examine cardiovascular reactivity
to stress as a function of histories of MDD.
The potential clinical relevance of the disturbances seen in both the SNS and HPA-axis
biomarkers employed in the present study comes from the growing evidence from both animal
and human studies that chronic or severe stress exposure can result in persistent alterations in
neurobiological systems that are stress responsive, including the SNS and HPA-axes (Bremner
and Vermetten, 2001; Coplan et al., 1996; Heim et al., 2001; Ladd et al., 1996; Lindley et al.,
2004). PMDD is more recently conceptualized as a stress-related disorder, owing both to
greater traumatic stress rates in PMDD populations (Girdler et al., 2003; 2004; Golding et al.,
2000; Perkonnig et al., 2004; Wittchen et al., 2003) as well as greater chronic psychosocial
stress exposure (Girdler 1993; 1998). Not only may MDD itself be considered a chronic stressor
but there is robust clinical and experimental evidence that environmental stressors serve as a
pathogenic trigger to develop MDD (Kendler et al., 2004). While the phenotypic differences
seen in SNS stress reactivity in the present study between women with PMDD and those with
histories of MDD cannot be explained at present, the pattern of blunted SNS reactivity in the
PMDD cohort is consistent with animal and human studies suggesting that long-term activation
of the stress axes (due to repeated or severe stress) can manifest in hypo-responsiveness of the
system to subsequent stressors (DeBellis and Thomas, 2003; Lindley et al., 2004; Resnick et
al., 2005; Rosler, 1994; Young and Breslau, 2004), especially in the face of on-going chronic
stress (Heim et al., 2001).
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Consistent with the concept of allostatic load (McEwen and Stellar, 1993), we hypothesize that
in women, genetically vulnerable to develop PMDD (Kendler et al., 1998), the SNS-axis will
show cumulative long-term effects of the systems’ attempts to adapt to chronic/severe stress,
and that this will be manifested in blunted SNS reactivity to subsequent stressors. In contrast,
our results suggest that in women genetically vulnerable to develop MDD (Kendler et al.,
2001; 2006; Sullivan et al., 2000), hyper-reactivity of the stress axes may be sustained beyond
remission of the depressive episode as suggested by other research showing persistent HPA-
axis activation in euthymic individuals with histories of MDD (Kathol 1985; Young et al.
2000a). Exaggerated reactivity to stress is also consistent with enhanced allostatic load
(McEwen and Stellar, 1993), possibly resulting from chronic or severe stress exposure in those
vulnerable to MDD.
The persistent disturbance in not only SNS and HPA-axis function, but also in pain sensitivity,
that we noted in women free of current MDD but who had histories of MDD raises the
possibility that these alterations may reflect a trait, as opposed to state, characteristic of MDD
and thus underlie the neurobiological vulnerability to develop of MDD. This is consistent with
the suggestion that persistent dysregulation in stress responses to even mild stressors may form
the basis for the development of mood disorders (Heim et al. 2001), though longitudinal studies
would be needed to address this issue.
While this study reports evidence to suggest that both PMDD and histories of MDD are
associated with independent stress-related phenotypic profiles, we also obtained evidence that
histories of MDD may hold special relevance for PMDD women. For example, a history of
MDD was associated with diametrically opposite effects on basal cortisol concentrations in
PMDD and non-PMDD women since PMDD women with prior MDD had lower cortisol
concentrations relative to all other groups and statistically lower than the non-PMDD women
with similar MDD histories. While blunted HPA-axis activation has been previously
documented in PMDD (Chuong et al. 1985; Facchinetti et al. 1994; Giannini et al. 1990; Girdler
and Klatzkin 2006; Girdler et al. 2007; 1998; Roca et al. 2003; Straneva et al. 2002), since
those prior studies did not control for prior MDD, the effect may well have been driven by
greater rates of prior MDD in PMDD samples. That the HPA-axis is differentially affected by
histories of MDD in PMDD women also comes from other studies of the HPA-axis modulator,
allopregnanolone. Allopregnanolone is a GABAergic neuroactive steroid that negatively
modulates the HPA-axis to restore homeostasis following stress (Bitran et al. 1999; 2000; Brot
et al. 1997; Brussaard et al. 1999; Guo et al. 1995; Morrow et al. 1987). Our prior research has
shown that allopregnanolone reactivity to stress predicts PMDD symptoms, but only in PMDD
women with a history of MDD and not in PMDD with no history of MDD (Klatzkin et al.
2006b). Thus, there may be a special relevance of prior MDD related to the regulation of the
HPA-axis and symptomatology in PMDD.
Hypocortisolemia may also have special clinical relevance for PMDD patients as recent
evidence has indicated that blunted HPA axis function is associated with a number of stress-
related bodily disorders (Heim et al. 2000). Other evidence that histories of MDD differentially
impacted PMDD women comes from our results showing that only in women with a history
of MDD did PMDD women report greater unpleasantness during the cold pressor task and
more effort during the tourniquet ischemic task than non-PMDD women. Since PMDD is a
disorder characterized by heightened mood symptoms during the luteal phase of the menstrual
cycle when the laboratory study protocol took place, the greater negative ratings by PMDD
women with histories of MDD during the pain and stress tasks, that were not seen in non-
PMDD with prior MDD, may reflect an additive effect of PMDD and a prior history of MDD.
Thus, with respect to both HPA-axis activation and stress-induced mood states, a history of
MDD may provide a “context of vulnerability” for women with PMDD.
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However, it must be acknowledged that β-endorphin concentrations, also reflecting HPA-axis
activity (Tsigos and Chrousos 2002), did not differ as a function of either PMDD or prior MDD
status. Results pertaining to diagnosis-related differences in β-endorphin concentrations in
MDD (Hegadoren et al. 2009) or PMDD (Bloch et al. 1998; Chuong et al. 1985; Facchinetti
et al. 1994; Giannini et al. 1990; Hamilton and Gallant 1988; Rapkin et al. 1996) samples have
been mixed. While the absence of parallel findings for basal cortisol and β-endorphin
concentrations in the current study cannot be explained, since β-endorphin is released from the
anterior pituitary while cortisol is released from the adrenal cortex, it is possible that the absence
of parallel findings in our study reflects the differential regulation of the HPA-axis, including
its feedback mechanisms, by histories of MDD in PMDD and non-PMDD women. While the
elevated cortisol concentrations in non-PMDD women with prior MDD is consistent with the
vast majority of studies in patients with current MDD (Galard et al. 2002; Goodwin et al.
1993; Gotthardt et al. 1995; Young et al. 2000b) and is consistent with enhanced central drive
of the HPA axis, the lower cortisol concentrations in PMDD women with prior MDD (also
consistent with the vast majority of studies in PMDD women with unknown MDD histories;
(Girdler et al. 1998; Straneva et al. 2002) may reflect diminished central drive of the axis and/
or enhanced negative feedback by cortisol on both the hypothalamus and the anterior pituitary.
In the absence of adrenocorticotropin (ACTH) concentrations this must remain a speculative
hypothesis but, regardless of mechanism, the results do underscore existing evidence for
persistent alteration in the regulation of the HPA-axis in women with histories of MDD (Heim
et al. 2008; Karp et al. 2005; Kunzel et al. 2003; Plotsky et al. 1998) and add to that literature
by suggesting that the alteration in the axis is influenced differently in women who have current
comorbid PMDD.
While our study has many notable strengths, including the use of strict diagnostic criteria based
on structured interview and daily prospective ratings to establish the MDD and PMDD
diagnoses, respectively, as well as a comprehensive assessment of stress-relevant biomarkers
and pain response measures in order to address an innovative question related to the unique
versus shared phenotypic profiles of PMDD and MDD, it is not without its limitations. A clear
limitation to the present study relates to the small sample size in each of the PMDD × MDD
cells. This limited our ability to conduct correlational analyses examining the relationship of
stress-responsive measures to either pain sensitivity and/or symptom severity. Given the
exploratory nature of our study, in combination with the small cell sizes, we also did not adjust
for the number of different statistical tests and this must too be viewed as a limitation. As such,
the present results should be considered preliminary though these results should serve a
heuristic value for future studies designed to pursue such questions.
Another limitation to the study design concerns the fixed order of the pain and mental stress
tests. It could be argued that diagnosis-related differences in pain responses carried over to
influence diagnosis-related differences in responses to the mental stressors. While this cannot
be ruled out, it is unlikely because: 1) only non-PMDD women with prior MDD differed in
their pain sensitivity, yet all women with prior MDD (PMDD and non-PMDD) showed greater
BP responses to stress; 2) prior research from our laboratory in healthy non-PMDD and never
depressed individuals did counter-balance the order of pain testing and mental stress testing
using identical pain and stress tests employed in the present study, and we found no evidence
that order of events influenced responses to either the pain test or the mental stress test (Mechlin
et al. 2005) and; 3) 15 minutes of recovery and rest was interspersed between the two
conditions.
Finally, it could be argued that the heterogeneity of our sample with respect to histories of
sexual or physical abuse is a limitation of our study. While it must be acknowledged that the
inclusion of women with abuse histories was to meet the aims of the larger, on-going parent
investigation, their inclusion also increases the generalizability of our findings to both PMDD
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samples, since histories of abuse are reported in 40 – 80% of PMDD populations (Girdler et
al. 2003; 2004; 2007; Paddison et al. 1990) and to women with histories of MDD, since a
history of abuse is a known risk factor for the development of MDD (Weiss et al. 1999).
Moreover, even in non-PMDD and non-MDD samples, rates of abuse for women in the United
States are sobering. Population-based national surveys have indicated that 13%–27% of women
are sexually abused as children (Badgley 1984; Finkelhor et al. 1990; MacMillan et al. 1997).
When adult sexual abuse, battering, and other forms of physical abuse are included, more than
one third of women from the general population have had these experiences (Resnick et al.
1993). Consistent with the evidence linking histories of abuse to the development of MDD,
we did find that non-PMDD women with prior MDD were more likely to have an abuse history
than non-PMDD women with no prior MDD. However, this proportional difference is unlikely
to explain the MDD-related differences in the biological measures in our study since non-
PMDD women with prior MDD exhibited elevated cortisol and no difference in NE responses
– a pattern opposite to that typically associated with abuse histories (i.e., lower cortisol or
blunted cortisol response to challenge and elevated NE) (Bremner and Vermetten 2001;
Bremner et al. 1996; Heim et al. 2001; Newport et al. 2004; Resnick et al. 1995; Stein et al.
1997). Moreover, we statistically controlled for histories of abuse in all analyses. Thus, while
our sample is heterogeneous with respect to histories of abuse, we believe it is representative
of the population of women with mood disorders.
In summary, our results suggest that both PMDD and histories of MDD are associated with
unique phenotypic profiles with respect to stress-responsive measures and pain sensitivity,
though histories of MDD may also have special relevance to PMDD women. If these results
are confirmed, longitudinal studies designed to assess the predictive ability of persistent
disturbance in stress reactivity or pain sensitivity and subsequent risk for recurrence of
depressive episodes in women with a history of depression would be indicated and would
inform the design of future biobehavioral intervention studies.
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Mean (± SEM) Daily Mood Ratings Core Symptom Categories as a Function of PMDD and
Prior MDD Status
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Mean (± SEM) Cortisol as a Function of PMDD and Prior MDD Status
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Mean (± SEM) Change in Sympathetic Nervous System Factors from Baseline to Speech Stress
as a Function of PMDD and Prior MDD Status
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Mean (± SEM) Change in Norepinephrine from Baseline to Speech Stress as a Function of
PMDD and Prior MDD Status
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Mean (± SEM) Cold Pressor Pain Threshold and Tolerance as a Function of PMDD and Prior
MDD Status
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